Previous 10 | Next 10 |
PTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding PR Newswire - Blackstone investment accelerates innovative product pipeline - - PTC will leverage Blackstone's network and life sciences expertis...
Summary The standard of care treatments for PKU have safety issues and/or limited efficacy. Recent data showed meaningful efficacy for SYNB1934 in PKU and the company will proceed to phase 3 testing. PTC Therapeutics, a competitor has a phase 3 study underway in PKU. PKU i...
Cantor Fitzgerald was quick to defend PTC Therapeutics ( NASDAQ: PTCT ) after the rare disease-focused biotech announced Tuesday a pause in enrollment in its Phase 2 PIVOT-HD trial for Huntington's disease candidate PTC518 in the U.S. The enrollment in the global trial...
PTC Therapeutics ( NASDAQ: PTCT ), a biotech focused on rare disorders, fell ~14% pre-market Wednesday after the company said it paused enrollment in Phase 2 PIVOT-HD trial for Huntington's disease candidate PTC518 in the U.S. The decision follows a request made by the...
PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518 PR Newswire SOUTH PLAINFIELD, N.J. , Oct. 18, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) confirmed today that enrollment is active and ongoing for its Phase 2 PIVOT-HD t...
PTC Therapeutics ( NASDAQ: PTCT ), a biotech focused on rare disorders, traded sharply lower on Tuesday after Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ), its partner for spinal muscular atrophy (SMA) therapy Evrysdi, reported Q3 2022 results. According to a collaboration ...
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2022 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , Oct. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conferen...
PTC Therapeutics to Present Clinical and Real-World Evidence on Translarna™ at the Annual Congress of the World Muscle Society PR Newswire - Presentations include age of loss of ambulation and preservation of upper limb function following treatment with Translar...
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of PTC Therapeutics (NASDAQ: PTCT) (“PTC” or the “Company”). The investigations concern whether certain of the Company’s officers and directors brea...
PTC Therapeutics' 2022 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community PR Newswire - 2022 recipients include patient advocacy organizations from Brazil , Greece , Turkey , and the U.K. - SOUTH PLAINFIELD, N.J....
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....